Stockholm - Delayed Quote SEK

Immunovia AB (publ) (IMMNOV.ST)

Compare
0.6340 +0.0050 (+0.79%)
At close: 5:29 PM GMT+2
Loading Chart for IMMNOV.ST
DELL
  • Previous Close 0.6290
  • Open 0.6290
  • Bid 0.6210 x --
  • Ask 0.6300 x --
  • Day's Range 0.6040 - 0.6500
  • 52 Week Range 0.5140 - 4.7300
  • Volume 904,500
  • Avg. Volume 3,917,053
  • Market Cap (intraday) 107.597M
  • Beta (5Y Monthly) 2.53
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6000
  • Earnings Date Nov 27, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

www.immunovia.com

10

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IMMNOV.ST

View More

Performance Overview: IMMNOV.ST

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IMMNOV.ST
64.22%
OMX Stockholm 30 Index
7.59%

1-Year Return

IMMNOV.ST
9.17%
OMX Stockholm 30 Index
17.82%

3-Year Return

IMMNOV.ST
99.45%
OMX Stockholm 30 Index
11.45%

5-Year Return

IMMNOV.ST
99.54%
OMX Stockholm 30 Index
54.48%

Compare To: IMMNOV.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IMMNOV.ST

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    106.75M

  • Enterprise Value

    78.70M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    69.11

  • Price/Book (mrq)

    5.42

  • Enterprise Value/Revenue

    88.93

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -55.94%

  • Return on Equity (ttm)

    -153.82%

  • Revenue (ttm)

    885k

  • Net Income Avi to Common (ttm)

    -116.12M

  • Diluted EPS (ttm)

    -0.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    36.76M

  • Total Debt/Equity (mrq)

    44.17%

  • Levered Free Cash Flow (ttm)

    -62.27M

Research Analysis: IMMNOV.ST

View More

Company Insights: IMMNOV.ST

Research Reports: IMMNOV.ST

View More

People Also Watch